Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors

doi:10.1248/cpb.56.1400

	Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors
	Yang, Qiangang 2; Chen, Lill 2; He, Xuchang 2; Gao, Zhenting 1; Bai, Donglu2
刊名	CHEMICAL & PHARMACEUTICAL BULLETIN
	2008-10
卷号	56 期号:10 页码:1400-1405
关键词	SARS coronavirus 3CL protease cinanserin analogs inhibitor fluorescence resonance energy transfer-based assay
ISSN号	0009-2363
DOI	10.1248/cpb.56.1400
文献子类	Article
英文摘要	The severe acute respiratory syndrome (SARS) coronavirus 3CL protease is an attractive target for the development of anti-SARS drugs. In this paper, cinanserin (1) analogs were synthesized and tested for the in-hibitory activities against SARS-coronavirus (CoV) 3CL protease by fluorescence resonance energy transfer (FRET) assay. Four analogs show significant activities, especially compound 26 with an IC50 of 1.06 mu M.
WOS关键词	SARS CORONAVIRUS ; 3C-LIKE PROTEINASE ; GENOME SEQUENCE ; DERIVATIVES
WOS研究方向	Pharmacology & Pharmacy ; Chemistry
语种	英语
出版者	PHARMACEUTICAL SOC JAPAN
WOS记录号	WOS:000259672800005
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/272790]
专题	院士及顾问专家
通讯作者	Bai, Donglu
作者单位	1.E China Univ Sci & Technol, Sch Pharm, Shanghai 200237, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China;
推荐引用方式 GB/T 7714	Yang, Qiangang,Chen, Lill,He, Xuchang,et al. Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors[J]. CHEMICAL & PHARMACEUTICAL BULLETIN,2008,56(10):1400-1405.
APA	Yang, Qiangang,Chen, Lill,He, Xuchang,Gao, Zhenting,&Bai, Donglu.(2008).Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors.CHEMICAL & PHARMACEUTICAL BULLETIN,56(10),1400-1405.
MLA	Yang, Qiangang,et al."Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors".CHEMICAL & PHARMACEUTICAL BULLETIN 56.10(2008):1400-1405.